OBJECTIVE: As sex favorably modulates the natural history of chronic liver diseases and the risk for neoplastic evolution, our study aimed to ascertain whether female hepatocellular carcinoma (HCC) patients are also characterized by better prognosis. METHODS: The ITA.LI.CA (Italian Liver Cancer) database was used, including 1834 HCC patients (482 females, 1352 males) that were consecutively diagnosed. The following variables were considered: age, etiology, modality of diagnosis, earlier interferon treatment, bilirubin, alpha-fetoprotein levels, constitutional syndrome, portal thrombosis, metastasis, number and size of nodules, grading, Child-Pugh class, tumor-nodes-metastases and Cancer of the Liver Italian Program staging, and treatment. RESULTS: Female HCC patients were characterized by older age (P=0.0001), higher prevalence of HCV infection (P=0.0001), diagnosis more frequently by surveillance (P=0.003), higher alpha-fetoprotein levels (P=0.0055), lower prevalence of constitutional syndrome (P=0.03), portal thrombosis (P=0.04), and metastasis (P=0.0001). HCC in females was more frequently unifocal (P=0.0001), smaller (P=0.001), well differentiated (P=0.001), and of lower Cancer of the Liver Italian Program and tumor-nodes-metastases stage (P=0.0001 and 0.0001). However, females underwent curative treatments (transplantation, resection, percutaneous ablation) in the same percentage of cases as males. Finally, females had a significantly longer survival (median 29 [95% confidence interval (CI): 24-33] vs. 24 (22-25) months, P=0.0001). The difference was sharper [median 36 (CI: 31-41] vs. 17 (CI: 15-19)] when females undergoing surveillance were compared with males diagnosed incidentally or for symptoms. The Cox model also identified sex as an independent predictor of survival. When only patients undergoing surveillance were considered, no significant difference was observed. CONCLUSION: HCC in females has better prognosis, but this is possibly more because of higher compliance with surveillance than to real biological differences.

Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? / Farinati, F.; Sergio, A.; Giacomin, A.; Di Nolfo, M. A.; Del Poggio, P.; Benvegnù, L.; Rapaccini, G.; Zoli, Marco; Borzio, F.; Giannini, E. G.; Caturelli, E.; Trevisani, Franco; for the Italian Liver Cancer group, [; Andreone, Pietro; Bernardi, Mauro; Biselli, Maurizio; Caraceni, Paolo; Cantarin, M. C.; Casadio, R.; Frigerio, M.; Di Micoli, A.; Domenicali, M.; Li Bassi, S.; Magalotti, D.; Cappa, F. M.; Santi, V.; Zambruni, A.; Balsamo, C.; DI MARCO, Mariacristina; Vavassor, E.; Gilardon, L.; Mattiello, M.; Alberti, A.; Gatta, A.; Gios, M.; Covino, M.; Gasbarrini, G.; Baldan, A.; Cristofori, C.; Molaro, M.; Sala, M.; Risso, D. T. R.; Ghittoni, G.; Roselli, P.; Grazi, GIAN LUCA; Nardo, B.; Ravaioli, M.; Pinna, ANTONIO DANIELE; Rossi, C.; Giampalma, E.; Golfieri, R. ].; Domenicali, Marco. - In: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 0954-691X. - 21:10(2009), pp. 1212-1218. [10.1097/MEG.0b013e32831a86f8]

Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?

ANDREONE, PIETRO;BERNARDI, MAURO;DI MARCO, MARIACRISTINA;PINNA, ANTONIO DANIELE;
2009

Abstract

OBJECTIVE: As sex favorably modulates the natural history of chronic liver diseases and the risk for neoplastic evolution, our study aimed to ascertain whether female hepatocellular carcinoma (HCC) patients are also characterized by better prognosis. METHODS: The ITA.LI.CA (Italian Liver Cancer) database was used, including 1834 HCC patients (482 females, 1352 males) that were consecutively diagnosed. The following variables were considered: age, etiology, modality of diagnosis, earlier interferon treatment, bilirubin, alpha-fetoprotein levels, constitutional syndrome, portal thrombosis, metastasis, number and size of nodules, grading, Child-Pugh class, tumor-nodes-metastases and Cancer of the Liver Italian Program staging, and treatment. RESULTS: Female HCC patients were characterized by older age (P=0.0001), higher prevalence of HCV infection (P=0.0001), diagnosis more frequently by surveillance (P=0.003), higher alpha-fetoprotein levels (P=0.0055), lower prevalence of constitutional syndrome (P=0.03), portal thrombosis (P=0.04), and metastasis (P=0.0001). HCC in females was more frequently unifocal (P=0.0001), smaller (P=0.001), well differentiated (P=0.001), and of lower Cancer of the Liver Italian Program and tumor-nodes-metastases stage (P=0.0001 and 0.0001). However, females underwent curative treatments (transplantation, resection, percutaneous ablation) in the same percentage of cases as males. Finally, females had a significantly longer survival (median 29 [95% confidence interval (CI): 24-33] vs. 24 (22-25) months, P=0.0001). The difference was sharper [median 36 (CI: 31-41] vs. 17 (CI: 15-19)] when females undergoing surveillance were compared with males diagnosed incidentally or for symptoms. The Cox model also identified sex as an independent predictor of survival. When only patients undergoing surveillance were considered, no significant difference was observed. CONCLUSION: HCC in females has better prognosis, but this is possibly more because of higher compliance with surveillance than to real biological differences.
2009
21
10
1212
1218
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? / Farinati, F.; Sergio, A.; Giacomin, A.; Di Nolfo, M. A.; Del Poggio, P.; Benvegnù, L.; Rapaccini, G.; Zoli, Marco; Borzio, F.; Giannini, E. G.; Caturelli, E.; Trevisani, Franco; for the Italian Liver Cancer group, [; Andreone, Pietro; Bernardi, Mauro; Biselli, Maurizio; Caraceni, Paolo; Cantarin, M. C.; Casadio, R.; Frigerio, M.; Di Micoli, A.; Domenicali, M.; Li Bassi, S.; Magalotti, D.; Cappa, F. M.; Santi, V.; Zambruni, A.; Balsamo, C.; DI MARCO, Mariacristina; Vavassor, E.; Gilardon, L.; Mattiello, M.; Alberti, A.; Gatta, A.; Gios, M.; Covino, M.; Gasbarrini, G.; Baldan, A.; Cristofori, C.; Molaro, M.; Sala, M.; Risso, D. T. R.; Ghittoni, G.; Roselli, P.; Grazi, GIAN LUCA; Nardo, B.; Ravaioli, M.; Pinna, ANTONIO DANIELE; Rossi, C.; Giampalma, E.; Golfieri, R. ].; Domenicali, Marco. - In: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 0954-691X. - 21:10(2009), pp. 1212-1218. [10.1097/MEG.0b013e32831a86f8]
Farinati, F.; Sergio, A.; Giacomin, A.; Di Nolfo, M. A.; Del Poggio, P.; Benvegnù, L.; Rapaccini, G.; Zoli, Marco; Borzio, F.; Giannini, E. G.; Caturelli, E.; Trevisani, Franco; for the Italian Liver Cancer group, [; Andreone, Pietro; Bernardi, Mauro; Biselli, Maurizio; Caraceni, Paolo; Cantarin, M. C.; Casadio, R.; Frigerio, M.; Di Micoli, A.; Domenicali, M.; Li Bassi, S.; Magalotti, D.; Cappa, F. M.; Santi, V.; Zambruni, A.; Balsamo, C.; DI MARCO, Mariacristina; Vavassor, E.; Gilardon, L.; Mattiello, M.; Alberti, A.; Gatta, A.; Gios, M.; Covino, M.; Gasbarrini, G.; Baldan, A.; Cristofori, C.; Molaro, M.; Sala, M.; Risso, D. T. R.; Ghittoni, G.; Roselli, P.; Grazi, GIAN LUCA; Nardo, B.; Ravaioli, M.; Pinna, ANTONIO DANIELE; Rossi, C.; Giampalma, E.; Golfieri, R. ].; Domenicali, Marco
File in questo prodotto:
File Dimensione Formato  
2009 Eur J Gastr Hep HCC.pdf

Accesso riservato

Dimensione 137.88 kB
Formato Adobe PDF
137.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237257
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 52
social impact